Global Antibody Market by Types, (Monoclonal Antibodies, Polyclonal Antibodies, ADCs, And Others) by Technology, (Western Blotting, Flow Cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, And Others), by Applications (Proteomics, Drug Development, and Genomics), By End-users (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and CROs), and by Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)
Market Outlook:
The global antibody market was valued at USD 147,431.4 Million in 2019 and is projected to reach USD 318,482.1 Million by 2027, expanding at a CAGR of 10.1% during the forecast period. An antibody is a protein component of the body's immune system that recognizes and neutralizes foreign organisms such as bacteria and viruses. After being exposed to a foreign substance known as an antigen, antibodies stay in the blood and protect against further exposure to the antigen. The demand for antibodies is growing owing to the increasing demand of fast recovery, growing number of patients with diabetic and cardiovascular disorders, rising number of research and development activities, and quick diagnosis techniques for dreadful diseases. Research and development activities in monoclonal antibodies are expected to create lucrative opportunities for the global antibody market in the future.
Market Dynamics
Testing kits are now available, allowing medical personnel and clinicians to acquire lab-quality, real-time diagnostic findings in minutes. Technological breakthroughs have improved the capabilities of testing systems. For example, the rapid antigen test for coronavirus is presented in minutes, allowing for quick and accurate sickness diagnosis. Diseases are healed by administering the necessary antibodies in the form of a vaccination or drug. Researchers are concentrating on antigen detection technologies and developments.
The number of people living with diabetes is rapidly increasing. Screening and early detection have the potential to save lives and avoid serious problems. Self-monitoring of blood glucose (SMBG) allows people with diabetes to assess their own blood sugar levels using a glycemic reader and finger-prick technology. To achieve long-term glycemic management, SMBG technology employs lancets, test strips, and blood glucose metres. Diabetes causes nerves and blood arteries that control the heart and blood flow in the body to deteriorate over time. As a result, an exogenous protein, such as insulin, is injected into the body to regulate blood sugar levels which is anticipated to fuel the growth of the market during the forecast period.
The research and development sector is concerned with new efforts initiated by firms or governments in the development of new goods or services or the improvement of current ones. The primary focus is on biosimilar antibodies. In terms of worldwide expenditure, the research and development industry is at the top. An increase in the number of R&D activities in the pharmaceutical and biotechnology industries biotechnology sectors, an increasing emphasis on the behaviour of various kinds of antibodies attaching to antigens, and product advancements are expected to fuel the market.
Healthcare is one of the most heavily regulated businesses on the planet. Clinical institutions and organizations must follow regulatory rules to preserve the privacy of patient information and the protection of healthcare workers in order to avoid fraud. Biotechnology and pharmaceutical industries demand large investments. Antibodies, for example, are being studied in research. It takes time to develop monoclonal and polyclonal antibodies. Antibodies are coupled to antigens and injected into an organism for testing. The serum then collects the observation and transports it. When the research is finished, the samples are sent to the FDA permission is required. The implementation of stringent rules is projected to impede the entry of new market competitors.
Segmental Outlook
By Type Segment
Based on types, the global antibody market is divided into monoclonal antibodies, polyclonal antibodies, ADCs, and others. Their use in the treatment of illnesses such as coronavirus, monoclonal antibodies are expected to have a large share of the market over the forecast period. Increase in cancer patients throughout the world, ADCs used to treat malignant tumours are rapidly growing popularity. Monoclonal antibody drugs are expensive to manufacture, but they are widely available in the market, making them accessible to customers, which drives the market. Polyclonal antibodies are predicted to proliferate rapidly due to their ability to bind many antigen epitopes.
By Technology Segment
In terms of technology, the global antibody market is classified into western blotting, flow cytometry, ELISA, immunohistochemistry, immunofluorescence, immunoprecipitation, and others. Owing to the precision, the western blotting segment is expected to occupy a considerable proportion of the market over the projection period. Antibodies to HIV were detected as a consequence of the tests. Flow cytometry is thought to be rapidly expanding since it can do multi-parameter analysis on single cells inside a sample combination that is heterogeneous.
By Applications Segment
In terms of applications, the global antibody market is classified into proteomics, drug development, and genomics. Owing to the efficient mapping of drug-protein and protein-protein interactions, the proteomics sector is expected to occupy a major proportion of the market over the projected period. The drug development segment is expected to expand rapidly, since it facilitates the release of sophisticated drugs and vaccines following FDA clearance. Attributing to advancements in genetic research of an organism and chances for cancer patients using stem cell treatment, the genomics segment is predicted to increase at a significant rate.
By End-users Segment
Based on end-users, the global antibody market is classified as pharmaceutical and biotechnology companies, academic and research institutes, and CROs. The introduction of medicines and vaccines for horrible illnesses, pharmaceutical and biotechnology firms are expected to have a large proportion of the market throughout the predicted period. CROs are expected to increase at a high rate, since they assist clinical studies of newly marketed vaccines and medications prior to market release. As a comprehensive study of illnesses is completed and a deep understanding of antigen is supplied, the academic and research institutions segment is predicted to increase at a quick rate.
Region Wise Outlook
Based on regions, the global antibody market is fragmented into North America, Europe, Latin America, and Middle East & Africa. North America accounted for a significant share of the market in 2019. During the projected period, the market in Latin America, the Middle East and Africa, and Europe is expected to grow at a considerable CAGR. During the forecast period, North America is expected to have the greatest share. Stem cell treatment research and technological improvements are offering attractive prospects for participants in this field. Due to the increased frequency of chronic illnesses such as cardiovascular and blood illnesses, Europe is likely to occupy a significant market share. Due to research and development initiatives, Asia Pacific is a potential area for the antibody market. The collaboration of several medical institutes and academic institutions is expected to improve the situation.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Antibody Market
- Historical, Current and Projected Market Size in terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Antibody Market Performance
Segments
Key Segments Covered
By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- ADCs
- Others
By Technology
- Western Blotting
- Flow Cytometry
- ELISA
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Others
By Applications
- Proteomics
- Drug Development
- Genomics
By End-users
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- CROs
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- AbbVie Inc.
- YASHRAJ BIOTECHNOLOGY LTD.
- QIAGEN
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Cell Signaling Technology, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Merck KGaA
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Alexion Pharmaceuticals, Inc.
- GenScript
- Precision BioLogic Incorporated Liberty Materials Inc
- signal peak silica
- Eagle Materials, Inc.
Competitive Landscape
Key players in the market include AbbVie Inc., YASHRAJ BIOTECHNOLOGY LTD., QIAGEN, Novartis AG, Hoffmann-La Roche Ltd, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Merck KGaA , Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Inc., GenScript, and Precision BioLogic Incorporated. These players are considered as key manufacturers of the market based on different varieties of product availability, regional presence, better supply chain management system, and the increasing demand for the products. The players are adopting key strategies such as product development, geographical expansion, mergers and acquisition and many other strategies to increase their demand for global antibody market.
Video Summary for Antibody Market
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antibody Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antibody Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antibody Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antibody Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antibody Market Size & Forecast, 2017-2027
4.5.1 Antibody Market Size and Y-o-Y Growth
4.5.2 Antibody Market Absolute $ Opportunity
4.6 Global Antibody Market: Impact Of Key Regulations
Chapter 5 Global Antibody Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Antibody Market Size Forecast By Type
5.2.1 Monoclonal Antibodies
5.2.2 Polyclonal Antibodies
5.2.3 ADCS
5.2.4 Others
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Antibody Market Analysis and Forecast By Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Technology
6.1.2 Basis Point Share (BPS) Analysis By Technology
6.1.3 Absolute $ Opportunity Assessment By Technology
6.2 Antibody Market Size Forecast By Technology
6.2.1 Western Blotting
6.2.2 Flow Cytometry
6.2.3 ELISA
6.2.4 Immunohistochemistry
6.2.5 Immunofluorescence
6.2.6 Immunoprecipitation
6.2.7 Others
6.3 Market Attractiveness Analysis By Technology
Chapter 7 Global Antibody Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Antibody Market Size Forecast By Application
7.2.1 Into Proteomics
7.2.2 Drug Development
7.2.3 Genomics
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Antibody Market Analysis and Forecast By End-User
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-User
8.1.2 Basis Point Share (BPS) Analysis By End-User
8.1.3 Absolute $ Opportunity Assessment By End-User
8.2 Antibody Market Size Forecast By End-User
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Academic and Research Institutes
8.2.3 CROs
8.3 Market Attractiveness Analysis By End-User
Chapter 9 Global Antibody Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Antibody Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Antibody Analysis and Forecast
11.1 Introduction
11.2 North America Antibody Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Antibody Market Size Forecast By Type
11.6.1 Monoclonal Antibodies
11.6.2 Polyclonal Antibodies
11.6.3 ADCS
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 North America Antibody Market Size Forecast By Technology
11.10.1 Western Blotting
11.10.2 Flow Cytometry
11.10.3 ELISA
11.10.4 Immunohistochemistry
11.10.5 Immunofluorescence
11.10.6 Immunoprecipitation
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis By Technology
11.12 Absolute $ Opportunity Assessment By Technology
11.13 Market Attractiveness Analysis By Technology
11.14 North America Antibody Market Size Forecast By Application
11.14.1 Into Proteomics
11.14.2 Drug Development
11.14.3 Genomics
11.15 Basis Point Share (BPS) Analysis By Application
11.16 Absolute $ Opportunity Assessment By Application
11.17 Market Attractiveness Analysis By Application
11.18 North America Antibody Market Size Forecast By End-User
11.18.1 Pharmaceutical and Biotechnology Companies
11.18.2 Academic and Research Institutes
11.18.3 CROs
11.19 Basis Point Share (BPS) Analysis By End-User
11.20 Absolute $ Opportunity Assessment By End-User
11.21 Market Attractiveness Analysis By End-User
Chapter 12 Europe Antibody Analysis and Forecast
12.1 Introduction
12.2 Europe Antibody Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Antibody Market Size Forecast By Type
12.6.1 Monoclonal Antibodies
12.6.2 Polyclonal Antibodies
12.6.3 ADCS
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Europe Antibody Market Size Forecast By Technology
12.10.1 Western Blotting
12.10.2 Flow Cytometry
12.10.3 ELISA
12.10.4 Immunohistochemistry
12.10.5 Immunofluorescence
12.10.6 Immunoprecipitation
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis By Technology
12.12 Absolute $ Opportunity Assessment By Technology
12.13 Market Attractiveness Analysis By Technology
12.14 Europe Antibody Market Size Forecast By Application
12.14.1 Into Proteomics
12.14.2 Drug Development
12.14.3 Genomics
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 Europe Antibody Market Size Forecast By End-User
12.18.1 Pharmaceutical and Biotechnology Companies
12.18.2 Academic and Research Institutes
12.18.3 CROs
12.19 Basis Point Share (BPS) Analysis By End-User
12.20 Absolute $ Opportunity Assessment By End-User
12.21 Market Attractiveness Analysis By End-User
Chapter 13 Asia Pacific Antibody Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Antibody Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Antibody Market Size Forecast By Type
13.6.1 Monoclonal Antibodies
13.6.2 Polyclonal Antibodies
13.6.3 ADCS
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Asia Pacific Antibody Market Size Forecast By Technology
13.10.1 Western Blotting
13.10.2 Flow Cytometry
13.10.3 ELISA
13.10.4 Immunohistochemistry
13.10.5 Immunofluorescence
13.10.6 Immunoprecipitation
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis By Technology
13.12 Absolute $ Opportunity Assessment By Technology
13.13 Market Attractiveness Analysis By Technology
13.14 Asia Pacific Antibody Market Size Forecast By Application
13.14.1 Into Proteomics
13.14.2 Drug Development
13.14.3 Genomics
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Asia Pacific Antibody Market Size Forecast By End-User
13.18.1 Pharmaceutical and Biotechnology Companies
13.18.2 Academic and Research Institutes
13.18.3 CROs
13.19 Basis Point Share (BPS) Analysis By End-User
13.20 Absolute $ Opportunity Assessment By End-User
13.21 Market Attractiveness Analysis By End-User
Chapter 14 Latin America Antibody Analysis and Forecast
14.1 Introduction
14.2 Latin America Antibody Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Antibody Market Size Forecast By Type
14.6.1 Monoclonal Antibodies
14.6.2 Polyclonal Antibodies
14.6.3 ADCS
14.6.4 Others
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Latin America Antibody Market Size Forecast By Technology
14.10.1 Western Blotting
14.10.2 Flow Cytometry
14.10.3 ELISA
14.10.4 Immunohistochemistry
14.10.5 Immunofluorescence
14.10.6 Immunoprecipitation
14.10.7 Others
14.11 Basis Point Share (BPS) Analysis By Technology
14.12 Absolute $ Opportunity Assessment By Technology
14.13 Market Attractiveness Analysis By Technology
14.14 Latin America Antibody Market Size Forecast By Application
14.14.1 Into Proteomics
14.14.2 Drug Development
14.14.3 Genomics
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Latin America Antibody Market Size Forecast By End-User
14.18.1 Pharmaceutical and Biotechnology Companies
14.18.2 Academic and Research Institutes
14.18.3 CROs
14.19 Basis Point Share (BPS) Analysis By End-User
14.20 Absolute $ Opportunity Assessment By End-User
14.21 Market Attractiveness Analysis By End-User
Chapter 15 Middle East & Africa (MEA) Antibody Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Antibody Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Antibody Market Size Forecast By Type
15.6.1 Monoclonal Antibodies
15.6.2 Polyclonal Antibodies
15.6.3 ADCS
15.6.4 Others
15.7 Basis Point Share (BPS) Analysis By Type
15.8 Absolute $ Opportunity Assessment By Type
15.9 Market Attractiveness Analysis By Type
15.10 Middle East & Africa (MEA) Antibody Market Size Forecast By Technology
15.10.1 Western Blotting
15.10.2 Flow Cytometry
15.10.3 ELISA
15.10.4 Immunohistochemistry
15.10.5 Immunofluorescence
15.10.6 Immunoprecipitation
15.10.7 Others
15.11 Basis Point Share (BPS) Analysis By Technology
15.12 Absolute $ Opportunity Assessment By Technology
15.13 Market Attractiveness Analysis By Technology
15.14 Middle East & Africa (MEA) Antibody Market Size Forecast By Application
15.14.1 Into Proteomics
15.14.2 Drug Development
15.14.3 Genomics
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Middle East & Africa (MEA) Antibody Market Size Forecast By End-User
15.18.1 Pharmaceutical and Biotechnology Companies
15.18.2 Academic and Research Institutes
15.18.3 CROs
15.19 Basis Point Share (BPS) Analysis By End-User
15.20 Absolute $ Opportunity Assessment By End-User
15.21 Market Attractiveness Analysis By End-User
Chapter 16 Competition Landscape
16.1 Antibody Market: Competitive Dashboard
16.2 Global Antibody Market: Market Share Analysis, 2019
16.3 Company Profiles (Details - Overview, Financials, Developments, Strategy)
16.3.1 AbbVie Inc.
16.3.2 YASHRAJ BIOTECHNOLOGY LTD.
16.3.3 QIAGEN
16.3.4 Novartis AG
16.3.5 F. Hoffmann-La Roche Ltd
16.3.6 Cell Signaling Technology, Inc.
16.3.7 Bio-Rad Laboratories, Inc.
16.3.8 Agilent Technologies, Inc.
16.3.9 Becton, Dickinson and Company
16.3.10 Merck KGaA
16.3.11 Johnson & Johnson Services, Inc.
16.3.12 Bristol-Myers Squibb Company
16.3.13 Alexion Pharmaceuticals, Inc.
16.3.14 GenScript
16.3.15 Precision BioLogic Incorporated
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antibody Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antibody Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antibody Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antibody Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antibody Market Size & Forecast, 2017-2027
4.5.1 Antibody Market Size and Y-o-Y Growth
4.5.2 Antibody Market Absolute $ Opportunity
4.6 Global Antibody Market: Impact Of Key Regulations
Chapter 5 Global Antibody Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Antibody Market Size Forecast By Type
5.2.1 Monoclonal Antibodies
5.2.2 Polyclonal Antibodies
5.2.3 ADCS
5.2.4 Others
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Antibody Market Analysis and Forecast By Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Technology
6.1.2 Basis Point Share (BPS) Analysis By Technology
6.1.3 Absolute $ Opportunity Assessment By Technology
6.2 Antibody Market Size Forecast By Technology
6.2.1 Western Blotting
6.2.2 Flow Cytometry
6.2.3 ELISA
6.2.4 Immunohistochemistry
6.2.5 Immunofluorescence
6.2.6 Immunoprecipitation
6.2.7 Others
6.3 Market Attractiveness Analysis By Technology
Chapter 7 Global Antibody Market Analysis and Forecast By Application
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Application
7.1.2 Basis Point Share (BPS) Analysis By Application
7.1.3 Absolute $ Opportunity Assessment By Application
7.2 Antibody Market Size Forecast By Application
7.2.1 Into Proteomics
7.2.2 Drug Development
7.2.3 Genomics
7.3 Market Attractiveness Analysis By Application
Chapter 8 Global Antibody Market Analysis and Forecast By End-User
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-User
8.1.2 Basis Point Share (BPS) Analysis By End-User
8.1.3 Absolute $ Opportunity Assessment By End-User
8.2 Antibody Market Size Forecast By End-User
8.2.1 Pharmaceutical and Biotechnology Companies
8.2.2 Academic and Research Institutes
8.2.3 CROs
8.3 Market Attractiveness Analysis By End-User
Chapter 9 Global Antibody Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities by Region
9.1.2 Basis Point Share (BPS) Analysis by Region
9.1.3 Absolute $ Opportunity Assessment by Region
9.2 Antibody Market Size Forecast by Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis by Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Antibody Analysis and Forecast
11.1 Introduction
11.2 North America Antibody Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Antibody Market Size Forecast By Type
11.6.1 Monoclonal Antibodies
11.6.2 Polyclonal Antibodies
11.6.3 ADCS
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 North America Antibody Market Size Forecast By Technology
11.10.1 Western Blotting
11.10.2 Flow Cytometry
11.10.3 ELISA
11.10.4 Immunohistochemistry
11.10.5 Immunofluorescence
11.10.6 Immunoprecipitation
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis By Technology
11.12 Absolute $ Opportunity Assessment By Technology
11.13 Market Attractiveness Analysis By Technology
11.14 North America Antibody Market Size Forecast By Application
11.14.1 Into Proteomics
11.14.2 Drug Development
11.14.3 Genomics
11.15 Basis Point Share (BPS) Analysis By Application
11.16 Absolute $ Opportunity Assessment By Application
11.17 Market Attractiveness Analysis By Application
11.18 North America Antibody Market Size Forecast By End-User
11.18.1 Pharmaceutical and Biotechnology Companies
11.18.2 Academic and Research Institutes
11.18.3 CROs
11.19 Basis Point Share (BPS) Analysis By End-User
11.20 Absolute $ Opportunity Assessment By End-User
11.21 Market Attractiveness Analysis By End-User
Chapter 12 Europe Antibody Analysis and Forecast
12.1 Introduction
12.2 Europe Antibody Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Antibody Market Size Forecast By Type
12.6.1 Monoclonal Antibodies
12.6.2 Polyclonal Antibodies
12.6.3 ADCS
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Europe Antibody Market Size Forecast By Technology
12.10.1 Western Blotting
12.10.2 Flow Cytometry
12.10.3 ELISA
12.10.4 Immunohistochemistry
12.10.5 Immunofluorescence
12.10.6 Immunoprecipitation
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis By Technology
12.12 Absolute $ Opportunity Assessment By Technology
12.13 Market Attractiveness Analysis By Technology
12.14 Europe Antibody Market Size Forecast By Application
12.14.1 Into Proteomics
12.14.2 Drug Development
12.14.3 Genomics
12.15 Basis Point Share (BPS) Analysis By Application
12.16 Absolute $ Opportunity Assessment By Application
12.17 Market Attractiveness Analysis By Application
12.18 Europe Antibody Market Size Forecast By End-User
12.18.1 Pharmaceutical and Biotechnology Companies
12.18.2 Academic and Research Institutes
12.18.3 CROs
12.19 Basis Point Share (BPS) Analysis By End-User
12.20 Absolute $ Opportunity Assessment By End-User
12.21 Market Attractiveness Analysis By End-User
Chapter 13 Asia Pacific Antibody Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Antibody Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Antibody Market Size Forecast By Type
13.6.1 Monoclonal Antibodies
13.6.2 Polyclonal Antibodies
13.6.3 ADCS
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Asia Pacific Antibody Market Size Forecast By Technology
13.10.1 Western Blotting
13.10.2 Flow Cytometry
13.10.3 ELISA
13.10.4 Immunohistochemistry
13.10.5 Immunofluorescence
13.10.6 Immunoprecipitation
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis By Technology
13.12 Absolute $ Opportunity Assessment By Technology
13.13 Market Attractiveness Analysis By Technology
13.14 Asia Pacific Antibody Market Size Forecast By Application
13.14.1 Into Proteomics
13.14.2 Drug Development
13.14.3 Genomics
13.15 Basis Point Share (BPS) Analysis By Application
13.16 Absolute $ Opportunity Assessment By Application
13.17 Market Attractiveness Analysis By Application
13.18 Asia Pacific Antibody Market Size Forecast By End-User
13.18.1 Pharmaceutical and Biotechnology Companies
13.18.2 Academic and Research Institutes
13.18.3 CROs
13.19 Basis Point Share (BPS) Analysis By End-User
13.20 Absolute $ Opportunity Assessment By End-User
13.21 Market Attractiveness Analysis By End-User
Chapter 14 Latin America Antibody Analysis and Forecast
14.1 Introduction
14.2 Latin America Antibody Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Antibody Market Size Forecast By Type
14.6.1 Monoclonal Antibodies
14.6.2 Polyclonal Antibodies
14.6.3 ADCS
14.6.4 Others
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Latin America Antibody Market Size Forecast By Technology
14.10.1 Western Blotting
14.10.2 Flow Cytometry
14.10.3 ELISA
14.10.4 Immunohistochemistry
14.10.5 Immunofluorescence
14.10.6 Immunoprecipitation
14.10.7 Others
14.11 Basis Point Share (BPS) Analysis By Technology
14.12 Absolute $ Opportunity Assessment By Technology
14.13 Market Attractiveness Analysis By Technology
14.14 Latin America Antibody Market Size Forecast By Application
14.14.1 Into Proteomics
14.14.2 Drug Development
14.14.3 Genomics
14.15 Basis Point Share (BPS) Analysis By Application
14.16 Absolute $ Opportunity Assessment By Application
14.17 Market Attractiveness Analysis By Application
14.18 Latin America Antibody Market Size Forecast By End-User
14.18.1 Pharmaceutical and Biotechnology Companies
14.18.2 Academic and Research Institutes
14.18.3 CROs
14.19 Basis Point Share (BPS) Analysis By End-User
14.20 Absolute $ Opportunity Assessment By End-User
14.21 Market Attractiveness Analysis By End-User
Chapter 15 Middle East & Africa (MEA) Antibody Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Antibody Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Antibody Market Size Forecast By Type
15.6.1 Monoclonal Antibodies
15.6.2 Polyclonal Antibodies
15.6.3 ADCS
15.6.4 Others
15.7 Basis Point Share (BPS) Analysis By Type
15.8 Absolute $ Opportunity Assessment By Type
15.9 Market Attractiveness Analysis By Type
15.10 Middle East & Africa (MEA) Antibody Market Size Forecast By Technology
15.10.1 Western Blotting
15.10.2 Flow Cytometry
15.10.3 ELISA
15.10.4 Immunohistochemistry
15.10.5 Immunofluorescence
15.10.6 Immunoprecipitation
15.10.7 Others
15.11 Basis Point Share (BPS) Analysis By Technology
15.12 Absolute $ Opportunity Assessment By Technology
15.13 Market Attractiveness Analysis By Technology
15.14 Middle East & Africa (MEA) Antibody Market Size Forecast By Application
15.14.1 Into Proteomics
15.14.2 Drug Development
15.14.3 Genomics
15.15 Basis Point Share (BPS) Analysis By Application
15.16 Absolute $ Opportunity Assessment By Application
15.17 Market Attractiveness Analysis By Application
15.18 Middle East & Africa (MEA) Antibody Market Size Forecast By End-User
15.18.1 Pharmaceutical and Biotechnology Companies
15.18.2 Academic and Research Institutes
15.18.3 CROs
15.19 Basis Point Share (BPS) Analysis By End-User
15.20 Absolute $ Opportunity Assessment By End-User
15.21 Market Attractiveness Analysis By End-User
Chapter 16 Competition Landscape
16.1 Antibody Market: Competitive Dashboard
16.2 Global Antibody Market: Market Share Analysis, 2019
16.3 Company Profiles (Details - Overview, Financials, Developments, Strategy)
16.3.1 AbbVie Inc.
16.3.2 YASHRAJ BIOTECHNOLOGY LTD.
16.3.3 QIAGEN
16.3.4 Novartis AG
16.3.5 F. Hoffmann-La Roche Ltd
16.3.6 Cell Signaling Technology, Inc.
16.3.7 Bio-Rad Laboratories, Inc.
16.3.8 Agilent Technologies, Inc.
16.3.9 Becton, Dickinson and Company
16.3.10 Merck KGaA
16.3.11 Johnson & Johnson Services, Inc.
16.3.12 Bristol-Myers Squibb Company
16.3.13 Alexion Pharmaceuticals, Inc.
16.3.14 GenScript
16.3.15 Precision BioLogic Incorporated
Key Segments Covered
By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- ADCs
- Others
By Technology
- Western Blotting
- Flow Cytometry
- ELISA
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Others
By Applications
- Proteomics
- Drug Development
- Genomics
By End-users
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- CROs
By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
- AbbVie Inc.
- YASHRAJ BIOTECHNOLOGY LTD.
- QIAGEN
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Cell Signaling Technology, Inc.
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Merck KGaA
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Alexion Pharmaceuticals, Inc.
- GenScript
- Precision BioLogic Incorporated Liberty Materials Inc
- signal peak silica
- Eagle Materials, Inc.
Key players in the market include AbbVie Inc., YASHRAJ BIOTECHNOLOGY LTD., QIAGEN, Novartis AG, Hoffmann-La Roche Ltd, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Merck KGaA , Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Inc., GenScript, and Precision BioLogic Incorporated. These players are considered as key manufacturers of the market based on different varieties of product availability, regional presence, better supply chain management system, and the increasing demand for the products. The players are adopting key strategies such as product development, geographical expansion, mergers and acquisition and many other strategies to increase their demand for global antibody market.
Our Clients
FAQ Section
Some frequently asked quetions about this report!
Major Manufactures include AbbVie Inc., YASHRAJ BIOTECHNOLOGY LTD., QIAGEN, Novartis AG, Hoffmann-La Roche Ltd, Cell Signaling Technology, Inc., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, Merck KGaA , Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Alexion Pharmaceuticals, Inc., GenScript, and Precision BioLogic Incorporated.
The base year considered for the global antibody market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years, 2020 is an estimated year and the forecast is provided from 2021 to 2027.
The market is expected to witness growth at a fast pace with increase in terms of demand during 2019-2020 owing to the positive impact of COVID-19 pandemic on the global antibody market.
Pharmaceutical and biotechnology companies, academic and research institutes, and CROs are few of the key end use industries driving the market growth.
The global antibody market is anticipated to grow significantly during forecast period due increasing demand of fast recovery, growing number of patients with diabetic and cardiovascular disorders.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
In addition to market size (in USD Million) and Company Market Share (in % for base year 2019), other data such Macro-economic factors, COVID-19 Impact on the global antibody market is available in final report.
According to this Growth Market Reports, report, the market from global antibody market is likely to register a CAGR of 10.1% during period 2020-2027, with an anticipated valuation of USD 318,482.1 Mn by the end of the 2027.
Additional company profiles can be provided on request.
Related Reports
Some other reports from this category!
